Postmenopausal bone loss is primarily due to estrogen deficiency. Recent clinical observations demonstrate that GH increases bone mass in GH deficient patients. The present study investigates whether estrogen regulates GH action and GH receptor expression in osteoblasts.
Introduction
Postmenopausal osteoporosis is a condition primarily caused by the severe decrease of serum estrogen levels after cessation of ovarian function. The absence of estrogen results in an increase in bone turnover (Turner et al. 1994 (Turner et al. , 1995 and a negative bone remodeling balance, leading to bone loss and an increased fracture risk. The decrease in bone mass can be prevented by treatment with estrogens (Lindsay et al. 1976) . Although the result of estrogen replacement is obvious (Turner et al. 1994 (Turner et al. , 1995 , the cellular mechanism of action of this hormone is unclear. Estrogens exert both proliferative and differentiative effects on osteoblasts (Gray et al. 1987 , Slootweg et al. 1992 , accomplished via a high affinity estrogen receptor (Eriksen et al. 1988 , Komm et al. 1988 . However, the effects are usually of a small magnitude, suggesting that estrogens also interact with other hormones or cytokines to exert the in vivo effects.
Growth hormone (GH) is an important factor in the regulation of bone mass (for a review see Slootweg 1993) . GH-deficient patients show a reduced bone mass (Hyer et al. 1992 , Rosén et al. 1993 which can be treated with GH replacement therapy (Rosén et al. 1994) . GH has well documented effects on osteoblast proliferation and function (Slootweg l993 ) through a high affinity GH receptor (GHR) (Barnard et al. 1991 , Nilsson et al. 1995 . Estrogen has been shown to be a major regulator of GH binding in other tissues and cells. Female rats have 2-to 3-fold more liver GH binding sites than male rats (Maes et al. 1983) . Estradiol implants in male rats increase GHR expression in the liver and GH binding protein levels in the circulation (Carmignac et al. 1993) . GHR gene expression in rats is strongly and positively controlled by estradiol status (Gabrielsson et al. 1995) . In young GH transgenic mice, bone mass is increased compared with normal young animals (Sandstedt et al. 1996) . This increase is not observed in ovariectomized animals, indicating that estrogen, in that animal model, is a prerequisite for increased levels of GH to exert its stimulatory effect on bone mass. Furthermore, a recent study using ovariectomized/hypophysectomized rats suggested that the effect of ovarian hormone deficiency in cancellous bone is pituitary hormone dependent (Chen et al. 1995) .
However, no additive effect of estrogen and GH was seen on femoral bone mineral density in aged ovariectomized rats (Verhaeghe et al. 1996) .
The present study was designed to study a possible skeletal interaction of estrogen and GH at the cellular level. The results demonstrate that estrogen, at physiological concentrations, increases GHR number and potentiates GH action in osteoblasts.
Materials and Methods

Cell culture
Rat osteosarcoma cells (UMR 106·01) were cultured as described earlier (Salles et al. 1994) . The cells were grown in phenol red free Dulbecco's modified Eagle's medium (DMEM)/RPMI, 5% dextran coated charcoal treated fetal calf serum (DCC-FCS) prior to binding studies or proliferation assays. At confluency, they were cultured for 24 h in phenol red free DMEM/RPMI, 0·1% BSA prior to stimulation with 17 -estradiol (Sigma, St Louis, MO, USA).
Isolation and culture of human osteoblast-like (hOB) cells were done as described previously (Nilsson et al. 1995) . Cancellous bone was obtained from orthopedic surgery. None of the cell donors had any known endocrine-or metabolic bone disease. The samples were dissected into small fragments and then thoroughly washed in F12 (Gibco, Paisley, Strathclyde, UK). Subsequently the bone chips were transferred to 75 or 162 cm 2 culture flasks (Costar, Cambridge, MA, USA) and cultured in 1:1 DMEM/F12 (Gibco), containing 10% vol/vol fetal calf serum (FCS, Gibco), fungizone (500 µg/l, Gibco), gentamycinsulphate (50 mg/l, Sigma), L-glutamine (2 mmol/l, Gibco) and L-ascorbic acid (100 mg/l, Merck, KGaA, Darmstadt, Germany), in a humidified, 5% CO 2 atmosphere at 37 C. Osteoblastic phenotype of the cells was demonstrated by staining for alkaline phosphatase activity and release of osteocalcin and procollagen-1 into the culture media. In experiments where the effect of 17 -estradiol was tested, the hOB cells were precultured for 24 h in DMEM/Ham's F12 without phenol red, 10% DCC-FCS (prepared as described earlier (Slootweg et al. 1992) ), then 24 h in the same medium containing 0·5% DCC-FCS, after which the stimulation with 17 -estradiol took place. Cells were isolated from several patients varying in age and sex as indicated in results.
Binding studies
125
I-labeling of GH and binding experiments were performed in optimal binding conditions for the cells, as described earlier (Salles et al. 1994 , Nilsson et al. 1995 . Recombinant human GH (Genotropin) was a gift from Pharmacia (Stockholm, Sweden). GH was iodinated using iodogen (for hOB) or chloramine-T (for UMR 106·01) and repurified using a Sephadex G-75 column and a Sep-Pak C-18 reverse phase cartridge respectively. The specific activity ranged between 3·3 and 4·3 MBq/µg. The binding assay was performed in PBS, 1% BSA for hOB and binding buffer (DMEM/RPMI without phenol red, supplemented with 1% (wt/vol) BSA, penicillin/streptomycin and 20 m Tris-HCl, pH=7·4) for UMR 106·01. For UMR 106·01, binding of 100 000 c.p.m./ml in 1 ml (six well plates) was allowed during an overnight period at room temperature. For hOB, binding of 100 000 c.p.m./ml in 0·5 ml (24 well plates) was allowed during 4 h at room temperature. The incubation was terminated by washing the cells three times in ice-cold PBS. The cells were then solubilized in 1  NaOH, and the radioactivity was determined in a gamma counter. All determinations were carried out in triplicate or in quadruplicate. Specific binding was calculated as the difference between binding in the absence and in the presence of unlabeled GH (10 mg/l).
GH receptor cDNAs
To determine GHR mRNA levels in UMR 106·01 cells, a rat GHR probe was used. Antisense GHR 35 S-UTPlabeled RNA was synthesized from an EcoR1 linearized pT7T3 18U plasmid carrying a 560 base pair BamH1 fragment of the rat GHR complementary DNA (cDNA, Mathews et al. 1989) . The GHR cDNA fragment corresponds to a part of the extracellular domain of the GHR.
A 500 base pair fragment of exon 10 of the human GHR gene (Nilsson et al. 1995) was used for measurement of the GHR mRNA levels in human osteoblast-like cells. 35 S-labeled human GHR antisense RNA probe was generated with Sp6 polymerase from an EcoR1 linearized PGEM-7Z(+) plasmid, whereas human GHR sense RNA was generated with T7 polymerase from a BamH1 linearized plasmid.
RNAse protection solution hybridization assay
Total nucleic acids were prepared by homogenizing harvested cells with a polytrone in a buffer containing 1% (w/v) SDS, 20 m Tris-HCl (pH 7·5) and 4 m EDTA. The homogenized cells were digested by an overnight proteinase-K treatment and total nucleic acids were prepared by subsequent phenol-chloroform extraction, according to Durnam & Palmiter (1986) . The RNase protection solution hybridization assay was then carried out according to the protocol described by Mathews et al. (1986) . Protected RNA-RNA hybrids were precipitated with trichloroacetic acid, collected on glass fiber filters and counted in a scintillation counter. The signal was compared with a standard curve obtained by hybridization to known amounts of GHR mRNA. The intra-assay coefficient of variation for the human as well as the rat GHR assays was less then 10% in the range of 50-2500 amol RNA standard. The results were correlated to the DNA content as measured according to the method of Labarca & Paigen (1980) .
Proliferation assays
UMR 106·01 cells were plated at a density of 200 000 cells/well (six well plates) in DMEM/RPMI without phenol red, 5% DCC-FCS. After 24 h the medium was replaced by DMEM/RPMI, 0·1% BSA. After another 24 h, the medium was replaced with the same medium, now supplemented with 0·5% DCC-FCS, containing 17 -estradiol. HOB were plated at a density of 100 000 cells/well (24 well plates) in DMEM/F12 without phenol red, 10% DCC-FCS. After 96 h the medium was replaced by DMEM/F12, 0·1% BSA, 0·5% DCC-FCS. After another 24 h, the medium was replaced with the same medium containing 17 -estradiol. When the incubation with 17 -estradiol had lasted 6 h (in both the UMR 106·01 and the hOB), GH (50 ng/ml) was added. Thereafter, the cells were allowed to grow for another 24 (UMR 106·01) or 48 (hOB) h, after which the cell number was determined using a counting hemocytometer.
Statistical procedure
Values are given as means ... The statistical significance of differences between means were calculated by ANOVA followed by Student-Neuman-Keul's multiple range test.
Results
The proliferative response to GH treatment is dependent on the presence of 17 -estradiol
We first studied a possible interaction of 17 -estradiol and GH with regard to their proliferative effects on osteoblasts.
For this purpose we performed experiments in which rat osteosarcoma cells were incubated with 17 -estradiol for 6 h, followed by addition of GH (50 ng/ml) and incubation overnight. Under these conditions, neither GH nor 17 -estradiol stimulated cell proliferation (Fig. 1a) . However, a combination of 17 -estradiol (10 12 -10 8 ) with GH (50 ng/ml) induced a significant increase in cell proliferation. A maximal effect of 17 -estradiol together with GH (50 ng/ml) was seen with 10 10  17 -estradiol (160·1 15·5% of control=no GH, Fig. 1a) . A synergistic effect of 17 -estradiol and GH was both found on the number of cells (Fig. 1a) and on [ 3 H]thymidine incorporation (data not shown). Similar results were seen in hOB cells (Fig. 1b) . GH (50 ng/ml) increased cell proliferation in the presence of estradiol (10 10 ; 159·6 5·1% of control) but not in the absence of estradiol (105·3 2·5% of control).
-Estradiol increases 125 I-GH binding and GHR mRNA levels in rat osteosarcoma cells
A possible way by which the synergistic action of 17 -estradiol and GH can be accomplished, is that 17 -estradiol upregulates GHR expression in UMR 106·01 cells. To investigate this, we studied 125 I-GH binding and GHR mRNA levels after incubation with 17 -estradiol. A time dependent stimulation was observed as shown in Fig. 2 . After 2 h incubation with 17 -estradiol (10 12 ) an increase in GH binding was present (204·4 22·4% of control culture, P<0·01). Binding was maximal at 8 h (216·9 27·87%, P<0·01). The stimulation was decreased again at 24 h (152·3 12·8%, P<0·05). The same concentration of 17 -estradiol stimulating binding induced a similar rapid increase of GHR mRNA levels; at 2 h it was 332·1 26·4% of control value (P<0·01). This stimulation was maximal between 4 and 8 h (4 h: 371·1 1·1%, P<0·01, 8 h: 374·6 43·9%, P<0·05 of control) while no effect was seen at 24 h (Fig. 2) .
17 -estradiol induced an increase in GH binding as well as in GHR mRNA levels at an optimal concentration of 10 12  17 -estradiol (binding 144·9 3·1% P<0·01; mRNA 405·4 31·8% of control levels Fig. 3a) .
Human osteoblast-like cells express increased GH binding after stimulation with 17 -estradiol
17 -estradiol increased GH binding in hOB cells. Twelve hours incubation with 17 -estradiol induced a dose related stimulation of 125 I-GH binding, with an optimum at 10 12  (203·8 3·6% of control P<0·01, Fig. 3b ). The increase in GH binding was accompanied by an increase in GHR mRNA levels (10 10  17 -estradiol 125·6 8·4% of control, Fig. 3b ).
Discussion
The present study demonstrates a positive modulation by estrogen of GH action and GHR expression in rat osteosarcoma cells and human osteoblast-like cells. This is the first in vitro evidence for a regulation of GH action and GHR expression in osteoblasts by estrogens. It adds estrogen to other positive modulators of GH action and receptors in osteoblasts, i.e. retinoic acid, and insulin-like growth factor binding proteins (IGFBPs)-2, -3 and -5 (Ohlsson et al. 1993 , Slootweg et al. 1995 , 1996a . In contrast, IGFs-I and -II induce a decrease in GHR expression and activity (Slootweg et al. 1995) .
The potentiation of osteoblastic GH activity by estrogen might be accomplished not only by regulation of its receptor number, but also by modulation of its intracellular signaling mechanism, potentially interacting with the tyrosine kinase activities from the JAK-STAT, MAP IRS-1 ( JAK=just another kinase, STAT=signal transducer and activator of transcription, MAP=mitogen activated protein, IRS=insulin receptor substrate kinase) or annexin-1 pathways (Roupas & Herington 1994 , Salles et al. 1996 .
Conflicting results have been reported regarding whether estrogen regulates proliferation of rodent osteoblasts (Rickard et al. 1993 , Verhaar et al. 1994 , Kudo et al. 1995 , Kassem et al. 1996 , Rao et al. 1996 . In the present study, the lack of effect of estrogen by itself could either be due to only investigating short time stimulation of estrogen or to choosing very 'pure' culture conditions with a long preincubation period without serum, no phenol red in the culture media and no other growth factors in the medium. The potentiating effect of estrogen on GH activity might explain at least in part the moderate and sometimes inconsistent effects by GH on cultured cells. The presence of phenol red, acting as a weak estrogen (Berthois et al. 1986) , ensures that some activity of GH is detected. In our experiments, the culture media did not contain phenol red (and thus 'basal' estrogenic activity), which resulted in the absence of an effect of GH. However, when 17 -estradiol was added, an effect of GH was observed.
The present data give rise to the question whether estrogen enhances GH action. In GH transgenic mice, the effect of overexpression of GH on bone mass is observed only if the ovaries are present (Sandstedt et al. 1996) , in our osteoblast proliferation assay, the stimulatory effect of GH is just noticed when estrogen is present. Therefore, we hypothesize that estrogen modulates the GH response in vitro as well as in vivo.
In the present paper we demonstrate an interaction between GH and estrogen in vitro; the in vivo interaction between these two hormones has been known for a long time. GH plasma levels in both rats and humans are under the control of estrogen ( Jansson et al. 1985) . A positive correlation between GH levels and estrogen levels can be seen in both young and postmenopausal women (Ho 1990 ). Treatment of postmenopausal women with estradiol induces a stimulation of GH levels (Duursma 1984 , Dawson-Hughes et al. 1986 ). Thus, it looks like estrogens in vivo stimulate the effects of GH on osteoblasts in two ways: by inducing an increase in GH secretion and by enhancing GH action and GHR expression in osteoblasts. Hepatic IGF synthesis has long been known to be controlled by GH (Daughaday 1989) , indicating that some of the anabolic effect of GH on bone tissue may be exerted via liver produced IGF-I. The production of IGFBPs is strongly under the influence of GH, both in the liver and in bone (Schmid et al. 1989 , Jones & Clemmons 1995 . By modifying these, GH regulates the activity and bioavailability of IGFs towards bone in a positive manner. The influence of estrogen on the hepatic production of IGFs is not clear; it is obviously depending on the physiological status of the individual. Pharmacological estrogen concentrations are known to reduce both IGFs and GH in acromegalics (Wiedeman et al. 1976) , in postmenopausal women, oral estrogen replacement decreases IGFs in the circulation. However in bone cell cultures, it is obvious that estrogen increases IGF-I production and changes the IGFBPs (Schmid et al. 1989 , Ernst & Rodan 1991 , resulting in increased activity of IGFs. The enhanced IGF levels exert not only a direct action toward bone, but also they contribute to the magnitude of the GH action, as recent studies have shown that GH and IGF-I together have additive or synergistic effects (Fielder et al. 1996) .
We conclude that estrogen stimulates GH activity as well as GH binding and GHR mRNA levels. These findings indicate that estrogen potentiates the effect of GH at the receptor level.
